JP Guru it might pay to read the whole report. I think you...

JP Guru it might pay to read the whole report. I think you should mention that the study was started in 2017! THAT IS ONLY THE START!. Below is what was published by the ESMO on last week. Between March 2017 and June 2018, 50 patients were enrolled (ITT population), 50 patients received any study treatment (safety population), and 42 patients subse- quently received 32P microparticle implantation (PP popu- lation; Figure 1) at a median (range) of 31 (21-77) days from commencing chemotherapy. Median follow-up was 31.6 months [95% confidence interval (CI): 26.5-35.1 months]. Baseline characteristics of the ITT population are summa- rized in Table 1. Central review of the baseline PET scans identified seven patients (5 PP) with suspected liver me- tastases. One patient withdrew from the study following hospitalization for TEAEs which precluded 32P microparticle implantation and subsequently received 32P microparticles off-protocol (ITT population).